Holen Sie sich die Stockscreener-App
14.67
8.11%
1.10
Schlusskurs vom Vortag:
$13.57
Offen:
$13.42
24-Stunden-Volumen:
1.30M
Relative Volume:
0.72
Marktkapitalisierung:
$1.61B
Einnahmen:
$-249.00K
Nettoeinkommen (Verlust:
$-187.60M
KGV:
-5.868
EPS:
-2.5
Netto-Cashflow:
$-201.88M
1W Leistung:
+15.60%
1M Leistung:
-4.05%
6M Leistung:
+170.17%
1J Leistung:
+182.66%
1-Tages-Spanne:
$13.08
$14.84
1-Wochen-Bereich:
$12.61
$15.09
52-Wochen-Spanne:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.67 | 1.49B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Guggenheim | Buy |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
How sustainable is Amylyx Pharmaceuticals Inc. stock dividend payoutWeekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Is Amylyx Pharmaceuticals Inc. stock positioned for digital transformationWeekly Stock Recap & Consistent Growth Stock Picks - newser.com
Can Amylyx Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for growth ETFsOil Prices & Weekly Watchlist for Consistent Profits - newser.com
What the charts say about Amylyx Pharmaceuticals Inc. today2025 Year in Review & Stepwise Trade Signal Guides - newser.com
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidanceGap Up & Weekly Return Optimization Plans - newser.com
Real time social sentiment graph for Amylyx Pharmaceuticals Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for long term wealth buildingTrade Volume Report & Capital Protection Trade Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead - AOL.com
Real time alert setup for Amylyx Pharmaceuticals Inc. performanceWeekly Gains Summary & Growth Focused Stock Reports - newser.com
Is Amylyx Pharmaceuticals Inc. stock a defensive play in 2025July 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Trend analysis for Amylyx Pharmaceuticals Inc. this weekTrade Entry Report & Safe Capital Growth Plans - newser.com
What’s the recovery path for long term holders of Amylyx Pharmaceuticals Inc.Layoff News & Smart Allocation Stock Reports - newser.com
Measuring Amylyx Pharmaceuticals Inc.’s beta against major indicesIndex Update & Reliable Intraday Trade Plans - newser.com
Applying Wyckoff theory to Amylyx Pharmaceuticals Inc. stockWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Published on: 2025-11-13 23:21:08 - newser.com
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX - The Joplin Globe
Using portfolio simulators with Amylyx Pharmaceuticals Inc. included2025 Key Lessons & Safe Investment Capital Preservation Plans - newser.com
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):